All News

Two new biosimilar announcements are expected to increase the uptake of the biosimilar infliximab to Johnson & Johnson’s Remicade for rheumatoid arthritis, Crohn’s disease, and other inflammatory conditions.

Mark Gilmore, partial owner of compounding and specialty pharmacy QMedRx in Maitland, Fla., is one of several compounders who have been accused by the government of filing improper claims to the TRICARE program.

Omnicare agreed to settle claims that it conspired with Abbott Laboratories “to engage in a number of disguised kickback arrangements to increase overall use of Depakote,”

The Power of a Name

A new study suggests that the name of a biosimilar product could influence pharmacist confidence levels when dispensing a biosimilar in place of a reference biologic.

And as with what seems like every area of healthcare, changes and challenges to the vital supply chain have been coming and will continue to come for the foreseeable future.

Many pharmacists support FDA’s recent warning letters to drug stores, smoke shops, and other retailers over selling e-cigarettes, hookah tobacco, and cigars to minors.

Impossible Task

Managing the costs of specialty pharmaceuticals is a perpetual task for specialty pharmacists.

Somewhere in the United States, there may be a retail or specialty pharmacy that is not part of a group purchasing organization (GPO). If there is such a pharmacy, it is very hard to find.

Caught in the Middle

The furor over EpiPen pricing is simply the best publicized of many similar price hikes that have left patients unable to pay.

While FDA recently approved two new biosimilars for rheumatoid arthritis and other inflammatory diseases, questions remain about how quickly physicians and patients will embrace the new drugs.

Battling DIR Fees

The profitability of both chain and independent pharmacies is being affected by direct and indirect remuneration fees that insurers are retroactively charging pharmacies after filling Medicare Part D prescriptions.

In patients with COPD who have a history of exacerbations, a once-daily treatment regimen of combined fluticasone furoate and vilanterol was associated with fewer exacerbations than usual care without a greater risk of serious adverse events